IBRX:NASDAQ, ImmunityBio, Inc.

IBRX stock overview

ImmunityBio, Inc. (IBRX:NASDAQ) closed at $5.98 on November 16, 2026, down 0.66% on the day. The stock trades 51.9% below its 52-week high of $12.43 and 206.7% above its 52-week low of $1.95. Over the past year, it gained 184.8%. ImmunityBio, Inc. is part of the Health Care sector.

Key figures

Price
$5.98
Day change
-0.66%
Volume
12,799,375
Average volume
12,643,115
Market cap
6B+
52-week range
$1.95 – $12.43
50-day average
$8.59
200-day average
$7.97

Price action over the past year

In 252 trading sessions since November 14, 2025, IBRX closed higher on 123 days (49%). Its best day was February 18, 2026 (+41.86%) and its worst was March 24, 2026 (-21.12%). The stock moved 10% or more in a single session 22 times. It opened at least 5% above the previous day's high 5 times.

Recent signals

IBRX news

About ImmunityBio, Inc.

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

Similar stocks

Find more stocks like IBRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.